Tharimmune shares are trading higher after the company announced it received EMA feedback on its TH104 clinical program. The design and main features of the proposed Phase 2 study were deemed acceptable and general guidance was also provided for a future Phase 3 study.
Portfolio Pulse from Benzinga Newsdesk
Tharimmune shares rose following positive feedback from the EMA on its TH104 clinical program. The EMA approved the design of the Phase 2 study and provided guidance for a future Phase 3 study.
October 30, 2024 | 2:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tharimmune shares increased after receiving positive feedback from the EMA on its TH104 clinical program. The EMA approved the Phase 2 study design and provided guidance for a future Phase 3 study.
The EMA's approval of the Phase 2 study design and guidance for Phase 3 is a significant regulatory milestone for Tharimmune, likely boosting investor confidence and driving the stock price higher.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100